Novavax Stock Intrinsic Value – Nasdaq Up, Novavax Shares Increase 2.78% to $9.62
July 14, 2023
☀️Trending News
Novavax ($NASDAQ:NVAX) Inc., a leading biotechnology company focused on the discovery, development, and commercialization of vaccines, had a positive day at the stock market. On Tuesday, its shares went up by 2.78% to $9.62, following the overall trend of the NASDAQ that also closed higher. This increase in its stock price was a welcome development for the company, which has been investing heavily in researching and developing vaccines for various types of diseases. With continued progress being made in their research and development efforts, Novavax could soon become one of the leading vaccine providers in the industry.
Analysis – Novavax Stock Intrinsic Value
At GoodWhale, we recently conducted an analysis of NOVAVAX‘s wellbeing. Using our proprietary Valuation Line, we determined that the intrinsic value of NOVAVAX’s shares is around $124.5. However, NOVAVAX’s current stock is currently trading at $9.3, which means it is undervalued by a whopping 92.5%. This could be a great opportunity for investors looking to capitalize on this discrepancy. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Novavax. More…
| Total Revenues | Net Income | Net Margin |
| 1.37k | -1.16k | -84.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Novavax. More…
| Operations | Investing | Financing |
| -653.02 | -99.72 | -189.26 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Novavax. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.54k | 2.44k | -10.38 |
Key Ratios Snapshot
Some of the financial key ratios for Novavax are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 323.4% | – | -82.7% |
| FCF Margin | ROE | ROA |
| -54.9% | 92.6% | -45.9% |
Peers
The competition between Novavax Inc and its competitors is fierce. Moderna Inc, BioNTech SE, and Pfizer Inc are all major players in the vaccine industry, and each company is striving to develop the most effective vaccine possible. While Novavax Inc has made great strides in recent years, its competitors are not far behind.
– Moderna Inc ($NASDAQ:MRNA)
Moderna Inc is a clinical stage biotechnology company that discovers, develops, and commercializes therapeutics and vaccines based on RNA. As of 2022, Moderna Inc has a market cap of 48.32B and a ROE of 80.28%. Moderna Inc’s mission is to harness the power of RNA to revolutionize medicine and change the way diseases are prevented, treated, and cured.
– BioNTech SE ($NASDAQ:BNTX)
As of 2022, BioNTech SE has a market cap of 32.44B and a Return on Equity of 71.82%. The company is a German biotechnology company that develops and manufactures vaccines and antibody therapeutics. The company has developed a platform that allows it to rapidly design and produce custom-made vaccines and therapeutics.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a pharmaceutical company with a market cap of 247.45B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets safe, effective, and affordable human and veterinary medicines. The company is one of the world’s largest research-based pharmaceutical companies, with products available in more than 150 countries.
Summary
NOVAVAX recently had a positive trading session, with its stock price increasing 2.78% to $9.62. This is an encouraging sign for investors, as it suggests that the company is doing well and could be a good option for those looking to diversify their portfolios. The company is also continuing to expand into new markets, boosting its potential for future growth.
Investors should conduct thorough research and consider their own financial goals before investing in NOVAVAX. With its current successes, it looks like a promising investment opportunity.
